Treatment Made Digital
Exploring the intersection of technology and healthcare
WELT believes that software will treat the world.
WELT is a Samsung healthcare startup developing digital products with therapeutic efficacy, validated in randomized controlled trials, and approved/cleared by regulatory bodies for prescription use.
WELT is leveraging our consumer-tech DNA to restore homeostasis in 3 pillars of life—eating, sleeping, and exercising—through our digital therapeutics and digital biomarker platforms.
Our therapeutics modules complement our digital biomarker platform
to offer 360-degree care.
Our digital biomarker platform allows for continuous disease monitoring
and provides insights into patients’ health.
Our digital therapeutics platform complements
the monitoring with personalized treatment.
Digital therapeutics (DTx) deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders.
Source: Digital Therapeutics Alliance
Digital biomarkers are objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. The data collected is typically used to explain, influence and/or predict health-related outcomes.
Source: Digital Biomarkers Journal
Digital Therapeutics Leader in Korea
Industry Advisor for the
Ministry of Food and
Drug Safety (KFDA) on DTx
Co-chair of DTA
APAC Working Group
Partnership with multiple
We work with government institutions and top hospitals in Korea,
along with researchers and organizations worldwide.